PPA
DRNA

Parametric Portfolio Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Parametric Portfolio Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-76,037
Closed -$1.53M – 3731
2021
Q3 		$1.53M Sell
76,037
-9,834
-11% -$271K ﹤0.01% 2584
2021
Q2 		$3.21M Buy
85,871
+42,159
+96% +$1.29M ﹤0.01% 2153
2021
Q1 		$1.12M Buy
43,712
+15,815
+57% +$404K ﹤0.01% 3110
2020
Q4 		$615K Sell
27,897
-67,614
-71% -$1.49M ﹤0.01% 3286
2020
Q3 		$1.72M Sell
95,511
-41,082
-30% -$851K ﹤0.01% 2602
2020
Q2 		$3.47M Buy
136,593
+13,243
+11% +$285K ﹤0.01% 2127
2020
Q1 		$2.27M Buy
123,350
+61,265
+99% +$1.19M ﹤0.01% 2299
2019
Q4 		$1.37M Buy
+62,085
New +$1.25M ﹤0.01% 2900
2017
Q1 		– Sell
-11,796
Closed -$34K – 3827
2016
Q4 		$34K Buy
+11,796
New +$41.9K ﹤0.01% 3752
2016
Q2 		– Sell
-12,949
Closed -$69K – 3973
2016
Q1 		$69K Buy
+12,949
New +$81.7K ﹤0.01% 3904

Other funds holding DRNA

CAM
Close Asset Management London, United Kingdom $3.76B AUM 40.74% 1-Year Est. Return

Parametric Portfolio Associates's DRNA Position: Q4 2021 in Review

Parametric Portfolio Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 76,037 shares — an estimated $1.53M sold.

Parametric Portfolio Associates first reported a position in DRNA in Q1 2016 and held it in 10 quarters. The position peaked at $3.47M in Q2 2020. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Parametric Portfolio Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 76,037 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $1.53M.
  • Parametric Portfolio Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2016 and held it in 10 quarters.
  • Parametric Portfolio Associates's Dicerna Pharmaceuticals, Inc. position peaked at $3.47M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Parametric Portfolio Associates's 13F filing for Q4 2021, filed 15 Feb 2022.